Symbolbild · KI-generiert
SELLAS Life Sciences Group, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
SELLAS Life Sciences is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead candidate is galinpepimut-S, a peptide cancer vaccine targeting the WT1 protein, which is being investigated across a range of haematological and solid tumour types.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. | SLS | NASDAQ | 1,86 Mrd. USD |
| UroGen Pharma Ltd. | URGN | NASDAQ | 1,86 Mrd. USD |
| Nanobiotix S.A. | NBTX | NASDAQ | 1,86 Mrd. USD |
| Mesoblast Limited | MESO | NASDAQ | 1,83 Mrd. USD |
| Tyra Biosciences, Inc. | TYRA | NASDAQ | 1,90 Mrd. USD |
| Kardigan, Inc. | KARD | NASDAQ | 1,83 Mrd. USD |
| GH Research PLC | GHRS | NASDAQ | 1,92 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.